Outcome
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Arunjyoti Bio Ventures reported its Q2 FY26 results on 3 November 2025, showing a sharp swing to a loss. Revenue from operations fell to ₹533.65 lakhs from ₹871.24 lakhs in the previous quarter, while the company posted a net loss of ₹122.73 lakhs versus a profit of ₹204.54 lakhs in Q1 FY26. For the half-year, revenue declined to ₹1,404.89 lakhs from ₹1,644.89 lakhs in H1 FY25, with net profit halving to ₹81.81 lakhs. The auditor (PKF Sridhar & Santhanam LLP) issued an unmodified review report but included an Emphasis of Matter regarding a prior-period deferred tax correction that led to restated comparative figures. Total equity stood at ₹3,387.47 lakhs with borrowings of ₹2,357.59 lakhs, and operating cash flow remained positive at ₹790.63 lakhs.
The sharp quarter-on-quarter revenue drop and swing to a loss are negative signals for shareholders, suggesting weaker business momentum in Q2 FY26. However, the restatement is non-cash and the half-year remains profitable, so the long-term picture is less alarming.